Indication

As monotherapy for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), who have progressed on, or are intolerant to, platinum-based chemotherapy and/or anti PD-1/PD-L1 immunotheray

Medicine details

Medicine name:
sotorasib (Lumykras)
SMC ID:
SMC2443
Pharmaceutical company
Amgen Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
14 March 2022
SMC meeting date:
01 February 2022
Patient group submission deadline:
29 November 2021